NR3C2 and hydrops fetalis: Unlike type 2 diabetes where no other therapies had been shown to reduce the risk of HF outcomes,14 the SGLT‐2is were tested on top of the guideline recommended therapy for HF, namely angiotensin converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, beta‐blockers and mineralocorticoid receptor antagonists.